Summary
34.02 1.03(3.11%)11/06/2024
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.11 | -0.70 | 5.74 | -12.30 | -47.51 | -32.23 | 0.00 | -24.75 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 34.02 | |
| Open | 35.23 | |
| High | 35.24 | |
| Low | 33.63 | |
| Volume | 47,977 | |
| Change | 1.03 | |
| Change % | 3.11 | |
| Avg Volume (20 Days) | 210,412 | |
| Volume/Avg Volume (20 Days) Ratio | 0.23 | |
| 52 Week Range | 29.72 - 76.98 | |
| Price vs 52 Week High | -55.81% | |
| Price vs 52 Week Low | 14.45% | |
| Range | 5.04 | |
| Gap Up/Down | -1.55 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,539 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 53.00 | |
| Book Value | 4.6050 | |
| Earnings Per Share | -3.9170 | |
| EPS Estimate Current Quarter | -1.1400 | |
| EPS Estimate Next Quarter | -1.1800 | |
| EPS Estimate Current Year | -4.1200 | |
| EPS Estimate Next Year | -4.1400 | |
| Diluted EPS (TTM) | -3.9170 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -4.3283 | |
| Return on asset (TTM) | -0.3205 | |
| Return on equity (TTM) | -1.0211 | |
| Revenue TTM | 27,347,000 | |
| Revenue per share TTM | 0.7280 | |
| Quarterly Revenue Growth (YOY) | -0.1090 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 30,114,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.0705 | |
| Revenue Enterprise Value | 40.1748 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 43,841,900 | |
| Shares Float | 24,497,994 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 22.09 | |
| Institutions (%) | 38.13 | |
11/06 07:00 EST - globenewswire.com
Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earlier-line patients and combinations 3Q 2024 earnings per share (EPS) of $0.17 compared to 3Q 2023 EPS of $0.02 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
11/05 13:00 EST - zacks.com
Immunocore (IMCR) Upgraded to Buy: Here's Why
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immunocore (IMCR) Upgraded to Buy: Here's Why
Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
09/14 03:00 EST - globenewswire.com
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
09/12 16:05 EST - globenewswire.com
Immunocore to present at the 2024 Cantor Global Healthcare Conference
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore to present at the 2024 Cantor Global Healthcare Conference
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
08/30 11:40 EST - seekingalpha.com
Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak
In Q2 of 2024, sales of Kimmtrak were $75 million, which was a year-over-year increase of 32%. Two expansion opportunities are possible for Kimmtrak, which are using it as an adjuvant for uveal melanoma and 2nd-line advanced cutaneous melanoma. Data from the phase 1/2 study, using brenetafusp for the treatment of patients with high-grade serous ovarian cancer, to be presented as a poster at the upcoming ESMO 2024 conference.
Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak
In Q2 of 2024, sales of Kimmtrak were $75 million, which was a year-over-year increase of 32%. Two expansion opportunities are possible for Kimmtrak, which are using it as an adjuvant for uveal melanoma and 2nd-line advanced cutaneous melanoma. Data from the phase 1/2 study, using brenetafusp for the treatment of patients with high-grade serous ovarian cancer, to be presented as a poster at the upcoming ESMO 2024 conference.
08/12 04:12 EST - seekingalpha.com
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V.
Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal
Immunocore Holdings is a biotech company with a promising revenue trajectory in 2024, driven by its leading product, KIMMTRAK. IMCR has a diverse pipeline with potential value drivers like IMC-F106C for cutaneous melanoma and IMC-M113V for HIV. The main risks stem from the Company's heavy reliance on KIMMTRAK and potential clinical trial failures for other pipeline drugs, such as IMC-F106C and IMC-M113V.
08/11 06:53 EST - seekingalpha.com
Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Mohammed Dar - CMO Michael Yee - Jefferies Elias Lenard - JPMorgan Tyler Van - TD Cowen Eric Schmidt - Cantor Fitzgerald Michael Schmidt - Guggenheim Jack Allen - Baird Justin Zelin - BTIG Jonathan Chang - Leerink Securities Ahu Demir - Ladenburg Thalmann Avantika Joshi - Mizuho Naureen Quibria - Capital One Securities Rajan Sharma - Goldman Sachs Ethan Markowski - Needham & Company Operator Welcome to the Immunocore Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Conference Call Participants Clayton Robertson - Head of Investor Relations Bahija Jallal - CEO Brian Di Donato - CFO and Head of Strategy Ralph Torbay - Head, Commercial David Berman - Head, R&D Mohammed Dar - CMO Michael Yee - Jefferies Elias Lenard - JPMorgan Tyler Van - TD Cowen Eric Schmidt - Cantor Fitzgerald Michael Schmidt - Guggenheim Jack Allen - Baird Justin Zelin - BTIG Jonathan Chang - Leerink Securities Ahu Demir - Ladenburg Thalmann Avantika Joshi - Mizuho Naureen Quibria - Capital One Securities Rajan Sharma - Goldman Sachs Ethan Markowski - Needham & Company Operator Welcome to the Immunocore Conference Call and Webcast. At this time, all participants are in a listen-only mode.
08/06 10:41 EST - investorplace.com
3 Small-Cap Stocks with Significant Growth Potential
The Federal Reserve seems prepared to cut interest rates, perhaps by its next meeting in September. That's one reason that institutional dollars are starting to rotate into small-cap growth stocks.
3 Small-Cap Stocks with Significant Growth Potential
The Federal Reserve seems prepared to cut interest rates, perhaps by its next meeting in September. That's one reason that institutional dollars are starting to rotate into small-cap growth stocks.
06/01 08:00 EST - globenewswire.com
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
05/31 16:05 EST - globenewswire.com
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
05/30 16:00 EST - globenewswire.com
Immunocore to present at the Jefferies Global Healthcare Conference
Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore to present at the Jefferies Global Healthcare Conference
Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
05/29 07:00 EST - globenewswire.com
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
05/24 12:00 EST - barrons.com
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
The American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual meeting. Companies such as GSK, Moderna, BioNTech, Gilead, and many others will reporting their progress.
05/08 07:00 EST - globenewswire.com
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $70.3 million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024 Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02) clinical data in post-checkpoint late-line cutaneous melanoma selected for oral presentation at ASCO 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
04/24 10:00 EST - globenewswire.com
Immunocore announces upcoming presentation and posters at ASCO 2024
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore announces upcoming presentation and posters at ASCO 2024
Immunocore announces upcoming presentation and posters at ASCO 2024 Phase 1 expansion data in immune checkpoints pre-treated cutaneous melanoma for brenetafusp (IMC-F106C targeting PRAME) to be presented during oral abstract session (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
04/04 16:00 EST - globenewswire.com
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
03/13 11:07 EST - investorplace.com
Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio
Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest.
Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio
Since Bill Gates left his position with Microsoft (NASDAQ: MSFT ) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest.
03/05 16:30 EST - globenewswire.com
Immunocore presented two posters at CROI 2024
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
Immunocore presented two posters at CROI 2024
Immunocore presented two posters at CROI 2024 Preclinical data highlights importance of TCR biology in development of new HIV treatments (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md.
02/28 10:57 EST - seekingalpha.com
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript